Stock Update On Mslp, Hbio, Psid From Pennytobuck.com
MusclePharm to Pursue PEPFAR and Global Fund for HIV/AIDS Procurement of Recon
MusclePharm Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States with a proprietary formulation used in eight performance products, reported the appointment of Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development.
Cory Gregory, MusclePharms President stated We are thrilled to have Ms. Selbovitz join the MusclePharm team as we enter the therapeutic, nutritional supplementation market that is focused on products to meet the nutritional requirements of people living with HIV/AIDS.
The Global Fund to Fight AIDS, Tuberculosis and Malaria is an international financing institution that invests the worlds money to battle disease. To date, it has committed US$19.3 billion in 144 countries to support large-scale prevention, treatment and care programs against these three diseases.
Mr. Gregory continued, We believe Ms. Selbovitz expertise and experience in the field of HIV will assist us secure distribution of MusclePharm products, such as Recon, to people living with the HIV disease in developing nations thru The Global Fund to Fight AIDS, Tuberculosis and Malaria, and The Presidents Emergency Plan for AIDS Relief (PEPFAR).
PEPFAR was launched in 2003 by President George W. Bush, and is the largest effort by any nation to combat a single disease with $18 billion dollars dedicated to fight HIV/AIDS in developing nations over the five year period of 2003-2008. In the first five years of the program, PEPFAR focused on establishing and scaling up prevention, care and treatment programs. It achieved success in expanding access to HIV prevention, care and treatment in low-resource settings.
Ms. Selbovitz is a graduate of Cornell University and received her Masters in Public Health at the Johns Hopkins University Bloomberg School of Health. She worked as the Client Intake Specialist at Positive Health Project and Syringe Exchange Program Coordinator at the Foundation for Research on Sexually Transmitted Diseases (STDs) and is a partner in BioEquity Partners.
Selbovitz is also a member of the Cornell AIDS Clinical Trials Group Community Advisory Board and AIDS Treatment Advocacy Coalition. She presented at the 5th European Conference on Clinical and Social Research on AIDS and Drugs, International Conference on Antiviral Research, 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention and XVIII International AIDS Conference.
For more information on MSLP, please visit www.musclepharm.com.
Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, recently announced that it has acquired the business of Coulbourn Instruments through a purchase of substantially all of Coulbourn's assets.
Coulbourn Instruments is a privately held manufacturer of behavioral measurement products, with a strong focus on systems for assessing learning and memory utilized in research laboratories. This acquisition is complementary to the current HBIO behavior research products, thereby strengthening HBIO's position in this approximate $40-50 million market.
Chane Graziano, CEO of Harvard Bioscience, commented, "The acquisition of Coulbourn provides us another well established brand in our portfolio of products and enables us to provide our customers a broader range of tools, expanded technical support and a strong direct sales team in the behavior research market. Additionally, we expect this acquisition to be immediately accretive to earnings and, going forward, we expect to add approximately $4 million in annual revenues."
Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. HBIO sells its products to thousands of researchers in over 100 countries primarily through its 850 page catalog (and various other specialty catalogs), its website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany and Spain with additional facilities in France and Canada. For more information on HBIO, please visit www.harvardbioscience.com.
PositiveID Corporation (Nasdaq:PSID) and its development partner RECEPTORS LLC ("Receptors") announced their plans to develop a product to capture salmonella for detection and diagnostics, and potentially other food-borne illnesses such as E.coli. PSID believes the Combinatorial Artificial Receptor Array (CARA) technology is able to optimize a faster, more efficient sample preparation procedure, which, in turn, translates to a more economical and accurate test and higher throughput for detecting salmonella and other bacteria.
The patented CARA platform is designed to be adaptable to a broad spectrum of applications in the medical, environmental and agricultural industries. Built on the foundation of its core CARA technology, Receptors' direct capture systems can provide more efficient capture of microbes for increased sanitation of sensitive environments, including food processing facilities.
A nationwide recall of eggs possibly contaminated with salmonella was initiated in mid-August. More than half a billion eggs have now been recalled. Many salmonella infections are due to ingestion of contaminated food. About 142,000 Americans are infected each year with salmonella enteritidis from chicken eggs. The shell of the egg may be contaminated by feces or environment, or its interior (yolk) may be contaminated from the shell or from an infected hen.
Receptors' has demonstrated its CARA SMART MATERIALS technology in a variety of sample processing applications, including the efficient capture of bacteria from urine samples for urinary tract infection (UTI) diagnostics, facile capture of intact bacteria versus free DNA for PCR-based analysis of infectious agent antibiotic sensitivity, efficient capture of influenza virus as the basis for a flu strain diagnostic, as well as broad spectrum microbe capture including salmonella for both sample preparation and sanitation applications.
PositiveID Corporation develops and markets healthcare and information management products through its RFID-based diagnostic devices and identification technologies, and its proprietary disease management tools. PositiveID operates in two main divisions: HealthID and ID Security. For more information on PositiveID, please visit www.PositiveIDCorp.com.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations.The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and twenty five thousand dollars in free trading stock from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
by: Bill Pennyman
Just Do It! Again and Again, Week After Week! Global Consumer Franchise Stocks Three Fast And Simple Ways To Build A Lucrative Opt In List Student Unions: Pros And Cons Of Their Functioning My Review Of Penny Stock Prophet Opening Statements: The Good, The Bad, And The Ugly Unique And Personal Gift Wres, Jmba And Eqlb Stock Update From Pennytobuck.com Gold Stock Update On Nsu, Anv And Orfg From Pennytobuck.com Stock Update On Tgmp And Sila From Pennytobuck.com Talks And Collaborations By Stella Vine Sila And Tgmp On Pennytobuck's Watchlist For August 24th, 2010 What Are Backlinks And How Do You Get Them?